[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351228-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-351228-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","a-real-world-multicenter-study-on-opportunistic-cervical-cancer-screening-in-hospital-in-china-comparison-of-truscreen-device-cytology-and-hpv-testing-for-detecting-high-grade-cervical-lesions","A real-world multicenter study on opportunistic cervical cancer screening in hospital in China - comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions","","A real-world multicenter, cross-sectional study in China evaluates the clinical performance of the optoelectronic device TruScreen (TS) for detecting high-grade cervical precancers in hospital-based opportunistic screening. Conducted across 64 hospitals from September 2018 to June 2021 with 14,982 women aged ≥20 years, TS results are compared with hrHPV testing, liquid-based cytology, and colposcopy with biopsy confirmation. Histopathology serves as the gold standard, and TS-based strategies are benchmarked against WHO-recommended guidelines, assessing diagnostic accuracy and referral balance.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-real-world-multicenter-study-on-opportunistic-cervical-cancer-screening-in-hospital-in-china-comparison-of-truscreen-device-cytology-and-hpv-testing-for-detecting-high-grade-cervical-lesions/351228/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-real-world-multicenter-study-on-opportunistic-cervical-cancer-screening-in-hospital-in-china-comparison-of-truscreen-device-cytology-and-hpv-testing-for-detecting-high-grade-cervical-lesions/351228.png","ImageObject",300,407,{"name":42,"@type":43},"Mia  ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary objective of this study?","Question",{"text":63,"@type":64},"To evaluate TruScreen’s clinical performance for detecting high-grade cervical precancers compared with standard screening methods (hrHPV testing, cytology, and colposcopy) in a hospital-based opportunistic cohort.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted and what population was included?",{"text":68,"@type":64},"A multicenter cross-sectional study was conducted across 64 hospitals in China from September 2018 to June 2021, including 14,982 women aged ≥20 years who underwent TS, hrHPV testing, LBC, and colposcopy with biopsy confirmation.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did TruScreen show compared with hrHPV testing and cytology?",{"text":72,"@type":64},"For CIN2+, TS had comparable sensitivity to hrHPV and higher specificity than cytology; TS also outperformed cytology in CIN3+ and maintained high negative predictive value (NPV).",{"name":74,"@type":61,"acceptedAnswer":75},"Which TS strategy performed best according to the results?",{"text":76,"@type":64},"The strategy combining TS with hrHPV testing (Strategy 3) achieved the lowest missed cancer cases and balanced referral rates while producing the best overall results among the compared methods.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},351228,1790703614,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Fei et al. BMC Cancer (2026) 26:362 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15590-6](https://doi.org/10.1186/s12885-026-15590-6)  \nRESEARCH Open Access  \nA real-world multicenter study   \non opportunistic cervical cancer screening in hospital in China: comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions  \nChen Fei1, Wen Chen2, Jun Liu3, Jiandong Wang4, Hongyan Guo5, Guonan Zhang6, Yu Zhang7, Qing Yang8, Renfeng Zhao9, Xuejun Chen10, Manhua Cui11, Weidong Zhao12, Jiahua Liu13, Yu-Ligh Liou14 and Jinghe Lang1*  \nAbstract  \nIntroduction Cervical cancer (CC) remains a major health challenge worldwide. Early detection methods and screening strategies are important for reducing both incidence and mortality rates.  \nObjectives This study evaluates the clinical performance of the real-time optoelectronic device, TruScreen (TS), in detecting high-grade cervical precancers compared to standard methods [high-risk human papillomavirus (hrHPV) testing, cytology, and colposcopy) in a Chinese hospital-based opportunistic screening cohort. In addition, assess the clinical effectiveness of the TS strategies alongside current guidelines and methodologies in cervical cancer screening. Methods A multicenter, cross-sectional study was conducted across 64 hospitals between September 2018 and June 2021 in China. Participants (n = 14,982 women aged ≥ 20 years) underwent TS test, hrHPV test, liquid-based cytology (LBC), and colposcopy with biopsy confirmation. Diagnostic performance [sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV)] were calculated using histopathology as the gold standard. Strategies incorporating TS test were compared to WHO-recommended guidelines.  \nResults For cervical intraepithelial neoplasia grade 2 and servier lesions (CIN2+), TS test demonstrated comparable sensitivity (87 . 0%; 95% CI: 84 .8–88. 9%) to hrHPV (91 . 9%) and higher specificity (57 . 2% vs. 29. 2%) than cytology (53 . 6%) . TS test demonstrated outperformed compared to cytology in CIN3+ (sensitivity: 90 . 0% vs. 62. 7%) and maintained high NPV (97 . 9%) . In women aged ≥ 45 years, TS test showed comparable sensitivity (88 . 5%) to hrHPV test (87 . 9%) and higher specificity (60 . 1%) than hrHPV (27 . 5%) and cytology (46 . 9%) in CIN3+ . Strategy 3, TS combined hrHPV testing, achieved the lowest missed cancer cases (n = 14) and balanced referral rates (19 . 65%), produced the best results among the methods compared.  \n*Correspondence: Jinghe Lang [langjh@aliyun.com](langjh@aliyun.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nFei et al. BMC Cancer (2026) 26:362 Page 2 of 13  \nConclusion The straightforward operation and non-invasive detection of TS test demonstrate high sensitivity and NPV, establishing it as","cbCaio9lungMuWb9","https://ap.wps.com/l/cbCaio9lungMuWb9","pdf",2396473,13,"English","# Introduction\n## Objectives\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What is the primary objective of this study?\",\"answer\":\"To evaluate TruScreen’s clinical performance for detecting high-grade cervical precancers compared with standard screening methods (hrHPV testing, cytology, and colposcopy) in a hospital-based opportunistic cohort.\"},{\"question\":\"How was the study conducted and what population was included?\",\"answer\":\"A multicenter cross-sectional study was conducted across 64 hospitals in China from September 2018 to June 2021, including 14,982 women aged ≥20 years who underwent TS, hrHPV testing, LBC, and colposcopy with biopsy confirmation.\"},{\"question\":\"What diagnostic performance did TruScreen show compared with hrHPV testing and cytology?\",\"answer\":\"For CIN2+, TS had comparable sensitivity to hrHPV and higher specificity than cytology; TS also outperformed cytology in CIN3+ and maintained high negative predictive value (NPV).\"},{\"question\":\"Which TS strategy performed best according to the results?\",\"answer\":\"The strategy combining TS with hrHPV testing (Strategy 3) achieved the lowest missed cancer cases and balanced referral rates while producing the best overall results among the compared methods.\"}]","A real-world multicenter study on opportunistic cervical cancer screening in hospital in China - comparison of TruScreen device, cytology, and HPV testing for detecting high-grade cervical lesions | PDF",1790093134,33,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d90bea2b4b915c849a2de24d71eb76d0.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8c6627ef8ee8472eb3126a3553469c5.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dc809cbe3822181c388691fbe916e03.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d17755b16624dec8b1b9481e925c30ab.webp",980,1306]